UK psychedelic medicines developer Beckley Psytech has said its candidate for treatment-resistant depression has enhanced the effect of standard antidepressants in a phase 2 trial.

Based on our experience and understanding of psychedelic therapy, here is our perspective on what the FDA guidance really means for psychedelic therapy clinical trials’ day-to-day work in trial ...